Can lacosamide be continued peri‑operatively, and what are the recommended dosing and monitoring guidelines when administering anesthesia?

Lacosamide and Anesthesia: Perioperative Management

Lacosamide can and should be continued perioperatively, with careful cardiac monitoring during the perioperative period, particularly if using IV administration or in patients with cardiac risk factors.

Continuation of Lacosamide Perioperatively

Lacosamide should not be abruptly discontinued for surgery. The FDA labeling explicitly states that lacosamide should be withdrawn gradually over at least 1 week to minimize increased seizure frequency 11. Abrupt discontinuation perioperatively would create unacceptable seizure risk that outweighs any theoretical anesthetic concerns.

Critical Cardiac Monitoring Requirements

The primary perioperative concern with lacosamide is cardiac conduction abnormalities, not drug interactions with anesthetics. The FDA labeling documents dose-dependent PR interval prolongation, with reports of bradycardia, AV block, ventricular tachyarrhythmia, and rarely asystole and cardiac arrest 11.

You must implement the following monitoring protocol:

• ECG monitoring should be continuous throughout anesthesia and recovery, as recommended by current anesthesia guidelines 2
• Obtain a baseline ECG before surgery if not recently available
• Monitor for PR interval prolongation, particularly if the patient is on other medications affecting cardiac conduction (beta-blockers, calcium channel blockers, sodium channel blockers) 11
• Watch for bradycardia (HR <50 bpm) and hypotension (SBP <90 mmHg) within 2 hours of any IV dose 34

Specific Perioperative Dosing Considerations

If the patient can take oral medications:

• Continue the patient's usual oral dose up to the morning of surgery
• Resume oral dosing as soon as feasible postoperatively 1

If IV administration is required:

• IV lacosamide can be substituted 1:1 for oral dosing 1
• Avoid loading doses in the perioperative setting unless absolutely necessary for status epilepticus, as loading doses increase the risk of CNS adverse effects (dizziness, ataxia) and cardiovascular complications 11
• If IV push administration is used (which is safe and more efficient than piggyback infusion), administer at a maximum rate of 80 mg per minute for doses ≤400 mg 354
• Standard infusion over 30-60 minutes is acceptable but less efficient 1

High-Risk Patient Populations Requiring Extra Vigilance

Exercise particular caution in patients with:

• Known cardiac conduction abnormalities (first-degree AV block, second-degree or higher AV block, sick sinus syndrome without pacemaker) 11
• Severe cardiac disease (myocardial ischemia, heart failure, structural heart disease) 11
• Cardiac sodium channelopathies (e.g., Brugada Syndrome) 1
• Concomitant medications affecting cardiac conduction 11
• Cardiovascular disease or diabetic neuropathy (increased risk of atrial fibrillation/flutter and syncope) 11

Dose Adjustments for Organ Dysfunction

Renal impairment:

• Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease: reduce maximum dose by 25% 1
• Post-hemodialysis: consider supplementation up to 50% of dose 1

Hepatic impairment:

• Mild to moderate hepatic impairment: reduce maximum dose by 25% 1

Drug Interactions with Anesthetic Agents

Lacosamide has minimal clinically significant drug interactions with anesthetic agents 6. The primary concern is additive cardiac conduction effects rather than pharmacokinetic interactions. There is no need to adjust anesthetic technique based on lacosamide use, but maintain heightened cardiac vigilance.

Postoperative Recovery Monitoring

Per Association of Anaesthetists 2021 guidelines, continue standard monitoring (ECG, SpO2, blood pressure) throughout recovery until the patient is stable 2. The ASA guidelines similarly recommend continuous cardiovascular monitoring during emergence and recovery 7. Given lacosamide's cardiac effects, this monitoring is particularly important and should continue until the patient demonstrates stable vital signs and cardiac rhythm.

Common Pitfalls to Avoid

• Do not discontinue lacosamide abruptly for elective surgery—seizure risk is unacceptable
• Do not use loading doses perioperatively unless treating active status epilepticus
• Do not assume lacosamide is "just another antiepileptic"—its cardiac effects require specific monitoring that differs from other antiepileptic drugs
• Do not forget to adjust doses in patients with renal or hepatic impairment